[HillsideManor]

Paul,

Great notes here and thanks for sharing.

Andy

[pdicamillo1]

Notes from the Annual Shareholders meeting:

Lifeloc Annual Shareholders meeting. June 4th, 2025

OTCID uplisting – allow for higher confidence in stock and trade volume

SpinDx is a platform technology with applications beyond drug testing.

Legalization only increases the need for rapid drug detection.

The recent U.S. DOT rule requiring the availability of oral fluids as a drug testing option aligns with the first SpinDx offering.

Spin Dx uses Immunoassay fluorophore tagged detection. Discriminating for psychoactive ?9-THC – current impairment. Demonstrated below 15 minutes.

First U.S. Utility and PCT patent applications filed, second is planned. Any drug can be detected. Just a method of developing the assay for that particular drug.

Hardware and firmware adjustments are still needed and being worked on.

SpinDx demonstrated detection panel in oral fluid or blood: – ?9-THC – Cocaine – Fentanyl – Amphetamine – Methamphetamine – Morphine – MDMA – Benzodiazepines

SpinDx includes drivers license bar code scan. Keyboard with manual Bluetooth entry and RFID badge.

Clear indication of results • Firmware customizable drug cutoff values for local requirements

Greater recurring revenue from higher value consumable disks, collection kits and firmware subscription.

Disks for different tests will be an ongoing development effort – Sample source: Oral fluid, blood, breath – Different drug panels – Testing beyond drugs of abuse. $25/test – higher value consumable.

Beta testing planned to begin soon - Completion of roadside ready test kit, where user collects sample, introduces to disk, and reads result

First product release (target: first quarter 2026) will be a reader, oral fluid collection kit and – First, ?9-THC pass / fail disk – Second, ?9-THC quantitative disk – Third, drug panel

Benefits of patent filed. 3 key developments. Achievement of multi-panel drug test on a single disk. Special antibodies for delta 9-thc. Separation technology. Improvement on Sandia technology separating metabolites so the detector only recognizes delta 9 thc

15 NG detection – human saliva. Full disk design needs to occur first. Molded samples of the disk will be received next week. Pass fail and quantitative will be the same disk but loaded with different reagents.

Beta testing – currently building box. Pieces are being assembled now.

Any chance of contacting the State of Colorado Office of Economic Development to request to use the portion of the grant money from 2014 that was never used? Has that organization checked in with you since the grant money was offered? Any chance of receiving a second grant from them?

More than a year ago. Worth giving them a shout out again. Have applied for a few grants. Have not been successful. Continue to look for grant opportunities. Have a grant package written up. Hopeful of grant money.

Is there a possibility that Lifeloc would form a collaboration with the NIST group as they are within a stone's throw from Lifeloc's headquarters and are working on similar devices for drug detection?

We want to engage with the NIST – currently have a nondisclosure agreement with the NIST. Currently pursuing collaboration.

Do you think Sandia would provide an investment or additional funding to help get SpinDx through the finish line? They seem to have the most knowledge of the device and its workings and it just seems like it would be a great fit for them to provide some form of assistance at this time. Any other recent updates from the team at Sandia in regards to the SpinDx device?

Funding probably not coming from Sandia. Nothing else Sandia can teach lifeloc about the device. Hardware is far advanced beyond what Sandia has. Thought about licensing their current device to Sandia – chose not to do that.

On the conference call 2 years ago, you explained that once the news flow starts it will continue to be more of a regular occurrence. Can you let us know how close we are to the beginning of seeing some news flow?

They have delayed news releases to avoid fatigue among customers and investors. We are there. The SpinDx has been taken to trade shows. Engage customers at this point. Ready to turn on the talks about SpinDx.

Would Lifeloc be willing to hire a local content creator and/or social media expert to create enticing marketing videos for Lifeloc. Most small and medium size businesses are benefitting tremendously from an increase in social media awareness. We have been trying for years to convince the team at Lifeloc that there is value in creating brand awareness whether it's service or product based. Just an idea but why not test it out for a year and see if it pays off. Try it for 1 year and if it does not create at least a 10x return then do not move forward with it in the future but we feel that hiring a social media expert is worth the effort and cost.

They agree. Time to ramp up marketing effort. Avoid spending money before it was ready. It is the time to do that.

Can the SpinDx device test for PED's? Does the device have a setting where it's capable of testing longer timeframes for the purpose of drug testing athletes for PED's for long term use? For example, can the SpinDx test for anabolic steroids use over an extended period of time? Some of these professional PED tests can cost up to $2,000/test and it would be wonderful to find out that Lifeloc can perform these tests for a fraction of the cost. Along the same lines, can the SpinDx device test for something like cocaine use over the course of a month or two. What I am trying to find out is if the SpinDx device has a setting that can test for recent, medium term and long term use of a particular drug.

PED’s – yes. We view that as the next market to tackle after drugs of abuse. Product lines up. Unsatisfied market. The industry is willing to spend for solutions. Same box and disk. Analysis will have to be customized. Develop that assay. Couple hundred thousand in funding to develop assay.

Cocaine metabolite life – weeks of lifetime. Have not optimized test for long term yet.

Any interest from the big boys at the recent shows and conferences where the SpinDx device has been showcased. Has anyone from the industry or even outside the industry showed interest in learning more or making a possible investment.

No investment or outside interest from big boys yet.

How much more money and/or funding do you think is needed to bring the SpinDx device to market?

$675,000 still looking to place. Had offers but not acceptable terms. Has to be the correct terms. Current funding is sufficient to get to launch.

For the last 5 years in each of the earnings reports we have been informed that the SpinDx device will be ready for commercialization and production. Each year this exact wording gets pushed into the next year. Can you let us know what is going to make this year any different than the previous years? Can we really expect commercialization of the device by early next year or will this be another occasion where it keeps getting pushed back another year.

They did not understand the complexity of the project. We currently do understand and pushed through the complexity. Ready to show the customers. Disk still needs to be optimized.
I'd like to focus on the topic of shareholder value for the next set of questions. As you know, Lifeloc stock has been stuck in a $2 range for over 3 years now. Volume has been on a downtrend and interest seems like it's at an all-time low. There have been no articles or blogs written about Lifeloc in years. If we compare the market caps of Lifeloc and Cannabix we see that Lifeloc is sitting just above $8 million and Cannabix is valued at $50 million. The market values Cannabix at an astounding 6 times that of Lifeloc. Cannabix has an accumulated deficit of over $35 million and has never produced any sales or revenue to date. Does anyone on the Lifeloc team actually think that Cannabix should be valued more than Lifeloc let alone 6 times? The only difference that I can see is they are willing to disseminate any and all news and they hired a PR firm to influence stock prices and maintain a positive narrative. Is it possible to put some effort into creating shareholder value for Lifeloc? I almost get the feeling that no one from the Lifeloc management team has any concern whatsoever about this topic.

They claim they do have concern. Directors have bought stock. Prioritize building the company over pushing a story. They claim they are at the inflection time. Less than 12 months away from taking revenue from spinDx. We are hopeful to see some real movement here in the stock.

As shareholders we would really love to see more updates and news flow coming from the Lifeloc team. Shareholders have been very patient with the ongoing delays, and despite the repetitive disappointments over many years, have continued to hold, and even add to our investment in Lifeloc Technologies. Had we put the same investment into almost any other security, we would have seen a better return. It's time to step up, and deliver - commercialization was supposed to occur 5 years ago, and here we are, still waiting for the quarterly reports, and annual meetings, only to be told that it will be delayed once again... We understand that this has been a tedious and complicated process but the licensing agreement with Sandia Labs and prototype device occurred over 10 years ago.

It’s been long enough. We will see this change now. We have positive things we can talk about in the lab. Time to get customers and investment community excited.

1. Lifeloc states that they can detect THC at a limit of 10ng/ml in saliva with the SpinDx device. Is this level of accuracy sufficient to meet the demands of the end user, as well as meet regulatory requirements to bring this device to market?

Depends on jurisdiction. They don’t want it to be too sensitive. 4 – 5 ng level. Used as a screening device. Do a screening test for $25 vs. evidential test for $200. For the Screening device – 10 ng is sufficient.

2. You have stated that there are flaws in the microfluidic action and full drug assay utilizing the current disk design, which have delayed Beta Testing. Have these design flaws been rectified? Will Beta Testing commence in the second quarter, as previously stated in the year end results? Note: There are only weeks remaining in Q2.

Design flaws with new disk design. Mold still needs to be built but key features are being received next week. Should have that answer in a couple weeks. Beta testing – short number of weeks. Doubt that testing will start in Q2 but moving along quickly.

3. With the popularity of Hemp derived beverages, gummies, etc, does the current device have the capability to accurately test for THC concentration from consumption of Hemp derived edibles and drinks?

Device will test the subject for THC. Doesn’t’ care how thc has entered the person.

[pdicamillo1]

Today's call in info for Lifeloc's annual stockholders meeting at 9:00 AM Mountain time:

[phone] code 725#

[Energy Manager]

Great job, thank you !

I have an important meeting this morning, but will check in after lunch.

Thanks again...

[pdicamillo1]

I can confirm that the CEO has received the questions and he expects that they will be addressed during the meeting. If you are unable to attend I will do my best to send a recap by the end of the day tomorrow. Here's a list of our questions if you or anyone else would like to review them:

For the upcoming Lifeloc shareholders meeting I would like to submit the following questions:


Any chance of contacting the State of Colorado Office of Economic Development to request to use the portion of the grant money from 2014 that was never used? Has that organization checked in with you since the grant money was first offered? Any chance of receiving a second grant from them?


Is there a possibility that Lifeloc would form a collaboration with the NIST group as they are within a stone's throw from Lifeloc's headquarters and are working on similar devices for drug detection?



Do you think Sandia would provide an investment or additional funding to help get SpinDx through the finish line? They seem to have the most knowledge of the device and its workings and it just seems like it would be a great fit for them to provide some form of assistance at this time. Any other recent updates from the team at Sandia in regards to the SpinDx device?



On the conference call 2 years ago, you explained that once the news flow starts it will continue to be more of a regular occurrence. Can you let us know how close we are to the beginning of seeing some news flow?



Would Lifeloc be willing to hire a local content creator and/or social media expert to create enticing marketing videos for Lifeloc. Most small and medium size businesses are benefiting tremendously from an increase in social media awareness. We have been trying for years to convince the team at Lifeloc that there is value in creating brand awareness whether it's service or product based. Just an idea but why not test it out for a year and see if it pays off. Try it for 1 year and if it does not create at least a 10x return then do not move forward with it in the future but we feel that hiring a social media expert is worth the effort and cost.



Can the SpinDx device test for PED's? Does the device have a setting where it's capable of testing longer timeframes for the purpose of drug testing athletes for PED's for long term use? For example, can the SpinDx test for anabolic steroids use over an extended period of time? Some of these professional PED tests can cost up to $2,000/test and it would be wonderful to find out that Lifeloc can perform these tests for a fraction of the cost. Along the same lines, can the SpinDx device test for something like cocaine use over the course of the past month or two if I wanted to test my child for use in the past? What I am trying to find out is if the SpinDx device has a setting that can test for recent, medium term and long term use of a particular drug.



Any interest from the big boys at the recent shows and conferences where the SpinDx device has been showcased. Has anyone from the industry or even outside the industry showed interest in learning more or making a possible investment.



How much more money and/or funding do you think is needed to bring the SpinDx device to market?



For the last 5 years in each of the earnings reports we have been informed that the SpinDx device will be ready for commercialization and production. Each year this exact wording gets pushed into the next year. Can you let us know what is going to make this year any different than the previous years? Can we really expect commercialization of the device by early next year or will this be another occasion where it keeps getting pushed back another year.



I'd like to focus on the topic of shareholder value for the next set of questions. As you know, Lifeloc stock has been stuck in a $2 range for over 3 years now. Volume has been on a downtrend and interest seems like it's at an all-time low. There have been no articles or blogs written about Lifeloc in years. If we compare the market caps of Lifeloc and Cannabix we see that Lifeloc is sitting just above $8 million and Cannabix is valued at $50 million. The market values Cannabix at an astounding 6 times that of Lifeloc. Cannabix has an accumulated deficit of over $35 million and has never produced any sales or revenue to date. Does anyone on the Lifeloc team actually think that Cannabix should be valued more than Lifeloc let alone 6 times? The only difference that I can see is they are willing to disseminate any and all news and they hired a PR firm to influence stock prices and maintain a positive narrative. Is it possible to put some effort into creating shareholder value for Lifeloc? I almost get the feeling that no one from the Lifeloc management team has any concern whatsoever about this topic.

As shareholders we would really love to see more updates and news flow coming from the Lifeloc team. Shareholders have been very patient with the ongoing delays, and despite the repetitive disappointments over many years, have continued to hold, and even add to our investment in Lifeloc Technologies. Had we put the same investment into almost any other security, we would have seen a better return. It's time to step up, and deliver - commercialization was supposed to occur 5 years ago according to the earnings reports, and here we are, still waiting for the quarterly reports, and annual meetings, only to be told that it will be delayed once again... We understand that this has been a tedious and complicated process but the licensing agreement with Sandia Labs and prototype device occurred over 10 years ago.



Additional questions from an investor who is unable to attend today’s shareholder meeting:

1. Lifeloc states that they can detect THC at a limit of 10ng/ml in saliva with the SpinDx device. Is this level of accuracy sufficient to meet the demands of the end user, as well as meet regulatory requirements to bring this device to market?

2. You have stated that there are flaws in the microfluidic action and full drug assay utilizing the current disk design, which have delayed Beta Testing. Have these design flaws been rectified? Will Beta Testing commence in the second quarter, as previously stated in the year end results? Note: There are only weeks remaining in Q2.


3. With the popularity of Hemp derived beverages, gummies, etc, does the current device have the capability to accurately test for THC concentration from consumption of Hemp derived edibles and drinks?

On behalf of long term investors, can you leave us with one thought that will keep us excited about continuing to be a Lifeloc shareholder. We just feel like the long-term Lifeloc shareholders deserve a little more attention and we all would benefit from an effort to create an increase in shareholder value.

[Energy Manager]

Feel free to submit them, if you think they are relevant. I am busy running my garden center, and unfortunately, don't have much free time during the spring, or I would have attended the annual shareholder meeting in person.

I would add, that shareholders, like you and I, have been very patient with the ongoing delays, and despite the repetitive disappointments over many years, have continued to hold, and even add to our investment in Lifeloc Technologies. Had we put the same investment into almost any other security, we would have seen a better return. It's time to step up, and deliver - commercialization was supposed to occur a couple of years before what they are now stating, and here we are, still waiting for their quarterly reports, and annual meetings, only to be told that it will still be more time... Their licensing agreement with Sandia Labs occurred 9 years ago... 9 years...

[pdicamillo1]

Would you like me to submit these questions along with mine in one email to Dr. Wilkomm or do you prefer to just email him with all of your questions?    

[pdicamillo1]

Excellent. Let's keep it going. I need to put in some additional effort but here's what I have so far:

I'd like to focus on the topic of shareholder value for the next set of questions. As you know, Lifeloc stock has been stuck in a $2 range for over 3 years now. Volume has been on a downtrend and interest seems like it's at an all-time low. There have been no articles or blogs written about Lifeloc in years. If we compare the market caps of Lifeloc and Cannabix we see that Lifeloc is sitting just above $8 million and Cannabix is valued at $50 million. The market values Cannabix at an astounding 6 times that of Lifeloc. Cannabix has an accumulated deficit of over $35 million and has never produced any sales or revenue to date. The only difference that I can see is they are willing to disseminate any and all news and they hired a PR firm to influence stock prices and maintain a positive narrative. Is it possible to put some effort into creating shareholder value for Lifeloc? I almost get the feeling that no one from the Lifeloc management team has any concern whatsoever about this topic. As shareholders we would really love to see more updates and news flow coming from the Lifeloc team.

Can the SpinDx device test for PED's? Does the device have a setting where it's capable of testing longer timeframes for the purpose of drug testing athletes for PED's for long term use? For example, can the SpinDx test for anabolic steroid use over an extended period of time? Some of these professional PED tests can cost up to $2,000/test and it would be wonderful to find out that Lifeloc can perform these tests for a fraction of the cost. Along the same lines, can the SpinDx device test for something like cocaine use over the course of a month or two. What I am trying to find out is if the SpinDx device has a setting that can test for recent, medium term and long term use of the particular drug.

Any interest from the big boys at the recent shows and conferences where the SpinDx device has been showcased. Has anyone from the industry or even outside the industry showed interest in learning more about the SpinDx device or making a possible investment.

How much more money and/or funding do you think is needed to bring the SpinDx device to market?

For the last 5 years in each of the earnings reports we have been informed that the SpinDx device will be ready for commercialization and production. Each year this wording gets pushed into the next year. What makes this year any different than the previous years? Can we really expect commercialization of the device by early next year or will this be another occasion where it keeps getting pushed back another year.

[Energy Manager]

Great idea...

I have some questions that are specific to the unit itself.

1. Lifeloc states that they can detect THC at a limit of 10ng/ml in saliva with the SpinDx device. Is this level of accuracy sufficient to meet the demands of the end user, as well as meet regulatory requirements to bring this device to market?

2. You have stated that there are flaws in the microfluidic action and full drug assay utilizing the current disk design, which have delayed Beta Testing. Have these design flaws been rectified? Will Beta Testing commence in the second quarter, as previously stated in the year end results? Note: There are only weeks remaining in Q2.

3. With the popularity of Hemp derived beverages, gummies, etc, does the current device have the capability to accurately test for THC concentration from consumption of Hemp derived edibles and drinks?

These are the first few questions that come to mind. I'm sure I will have several more before the meeting.

[pdicamillo1]

For the upcoming annual shareholders meeting that is set for Wednesday June 4th, I would like to get us all on the same page and brainstorm some questions to ask the management team. This is the one shot we have each year where we have their attention and we can get answers. I'd like us to put some focus on the topic of creating shareholder value. Lifeloc stock has been stuck in a $2 range for over 3 years now and I'd like to see some changes from management in this regard.

We can either individually submit our questions or put them together into one document/email and send it over by Monday. Maybe it's better if they get individual questions submitted as they can see that more than just one shareholder has an interest?

Either way let's get on top of this and fire away anything and everything that you can think of. If they have to spend an hour or two answering our questions then so be it. I don't want to miss anything and I'd love to hit all topics. We have their undivided attention and should use it.

Please put in some time and effort over this weekend and let's hit them with the best that we have. I will work on some questions and share them with the board and we can add to that and make changes. Let's get some good vibes flowing back into this thing.

[pdicamillo1]

Lifeloc is an exhibitor this week at the IPTM’s annual Symposium on Traffic Safety.

Breakout sessions include:

Roadside Oral Fluid Screening to Detect Impaired Drivers (Chuck DeWeese)
- Chuck DeWeese, Responsibility.org
In response to the rise in drug and multi-substance impaired driving, there is a pressing need for expanded drug testing on the roadside. For officers who are not specially trained in drug impairment detection, oral fluid screening can assist in identifying drivers who may have recently consumed drugs and would otherwise evade detection. This technology has proven to be an effective tool for SFST and/or ARIDE trained patrol deputies and officers who may not have extensive DRE training. This presentation will clarify what roadside oral fluid screening is and what it is not, how it is being Implemented across the country, and the successes observed in various states, with a particular focus on the Indiana roadside oral fluid screening program.

Lifeloc is a corporate sponsor and partner of Responsibility.org who is leading this particular session.

[Energy Manager]

Lifeloc has completed its application for the new OTCID market tier, effective July 1, 2025. We believe the new OTCID standards will create greater market confidence than the OTC Pink and allow a more liquid marketplace for our shareholders.

How the OTCID Will Work
The OTCID will operate by enhancing transparency and accountability within the Over-the-Counter (OTC) market. By introducing a structured framework for disclosures and certifications, both issuers and investors stand to benefit significantly. Here are some of the key advantages that the OTCID will bring:

Disclosure Requirements: Continuous disclosures and management certifications will ensure that investors receive more reliable information regarding companies’ operations and financial performance.
Accountability for Issuers: Companies will be held to a higher standard for their disclosures. This accountability will promote a culture of compliance, which can attract institutional investment.
Market Revitalization: The reclassification of companies under the new tier has the potential to reinvigorate interest in the OTC market by drawing in speculative investments.
Technological Integration: Utilizing a modern platform like OTCIQ will allow companies to benefit from various technological advancements, such as automated reminders for reporting deadlines, digital tools for disclosure preparation, and enhanced security features to safeguard sensitive information.
Facilitation of Capital Formation: OTCID will aid in facilitating capital formation by making it simpler for companies to demonstrate their compliance and transparency to prospective investors. This increased credibility could attract more institutional and retail investors to the OTC market.
By addressing these key areas, the OTCID aims to create a more robust and appealing environment for both issuers and investors.

Implications for Issuers
For companies operating within the OTC market, transitioning to OTCID presents both opportunities and challenges. Among the opportunities, increased visibility is a significant benefit, as compliance with new reporting requirements can enhance a company’s profile among transparency-focused investors. Additionally, meeting these disclosure standards may provide access to institutional capital, attracting investors who are typically cautious about engaging with less regulated environments.

However, there are challenges to consider as well. Compliance costs can be a burden, especially for smaller companies, as they may face increased expenses related to new reporting requirements and management certifications. Furthermore, there is a commitment to ongoing disclosure, requiring issuers to ensure they have sufficient resources to maintain compliance with continuous reporting obligations.

Implications for Investors
Investors stand to benefit significantly from these changes. Access to reliable information enables more informed investment decisions, particularly in the realm of micro-cap stocks. This access allows investors to evaluate their options more thoroughly and make choices based on comprehensive data. Additionally, the ability to distinguish compliant issuers from non-compliant ones aids in risk mitigation, helping investors avoid potential pitfalls associated with poorly managed or fraudulent companies. Furthermore, greater engagement opportunities arise as enhanced transparency encourages investors to engage with companies that demonstrate accountability and openness.

The Future Landscape of the OTC Market
Looking ahead, several trends are likely to shape the evolution of the OTC market:

Technological Integration: Enhances efficiency and transparency across trading processes.
Regulatory Developments: May lead to further improvements in reporting standards across financial markets.
Globalization Trends: International companies will seek opportunities in U.S. markets through platforms like OTCID.
The establishment of OTCID represents a significant step forward in creating a more organized and transparent environment within the OTC market. By prioritizing issuer engagement and accountability while protecting investor interests, this initiative has the potential to reshape how participants interact within this crucial segment of finance.

Conclusion
The launch of OTCID is more than just a regulatory change; it represents an evolution towards a more transparent marketplace that benefits all stakeholders involved. As we approach July 2025, it is essential for both issuers and investors to understand their roles within this new framework. Embracing transparency will ultimately foster stronger relationships between companies and their investors, creating an environment where informed decision-making prevails.

With these advancements on the horizon, stakeholders should remain vigilant and proactive in adapting their strategies within this changing landscape. The future looks promising as we move towards a more accountable financial ecosystem through initiatives like OTCID. This transformation could breathe new life into U.S. micro-cap markets, making them vibrant venues for capital raising and investment opportunities.

[Energy Manager]

Looks like Lifeloc has partnered with the Anschutz Medical Center in Colorado, and is ready to begin Beta testing with human subjects.

Total revenues increased by 6% compared to same quarter in 2024, gross profit increased 9% due to higher product sales in the last 3 months.

[pdicamillo1]

NIST is looking to partner with "other entities" to advance their marijuana breathalyzer design and development. Could be a nice opportunity for Llifeloc when the event occurs in September:

Earlier this year, meanwhile, NIST had been planning an April event to convene government officials, forensics experts, academics, industry representatives, law enforcement and standards organizations for what it described as “an open and candid discussion” about “the path forward to realize meaningful cannabis breathalyzer technology and implementation.”

A month ahead of the event, however, a NIST official told Marijuana Moment that the workshop had been postponed. The cannabis breathalyzer event has now been rescheduled for September.

Topics to be discussed will include challenges facing marijuana breathalyzer design and development, obstacles to prosecutors handling drugged-driving cases and how NIST and other entities might partner to advance the technology.

[pdicamillo1]

Looks like the NIST event "Building a Path Forward for Meaningful Cannabis Breathalyzer Realization" has been postponed again until late September:

[Energy Manager]

Everybody's doing it....

https://www.marijuanamoment.net/new-york-marijuana-sales-near-1-5-billion-total-as-number-of-stores-nearly-tripled-last-year-state-report-says/?fbclid=IwY2xjawJ-_39leHRuA2FlbQIxMQBicmlkETE0NERMQ2pYTlFZR0NQTU9EAR7ATVhIq0CZl4-KjFt1h04_6b11kElhZSqK_4CtpDHwMgG8GWAlfBvP1-AfIA_aem_O0svWANmgGsbIBpQU7kXmQ

[pdicamillo1]

Researching some sales/revenue for the SoToxa drug detection device and I found this article that explains the rebranding of the DDS2 device to the name SoToxa:

https://vancouvercriminallaw.com/saliva-testing-rebranding-and-the-not-so-new-abbot-sotoxa/

The line that I find most interesting is: "The manufacturers submitted their devices for testing in the hopes that they would win approval and sales of thousands of units to Canadian police forces would follow. But the Alere DDS2 also had problems."

If the SpinDx drug detection device actually receives Canadian approval it could equate to thousands of unit sales. 2,000 devices would more than double Lifeloc's revenue just from Canada.

Sadly the stock continues to drift lower with no buyers in sight. It appears that no investor interest was made from the LD Microcap conference or the IACP conference.

We should focus some questions at this years annual shareholders conference on creating shareholder value.

[pdicamillo1]

We could really use an update that describes the accuracy of the SpinDx Drug detection device. There is no information that explains how accurate SpinDx has been in the Beta testing phase. We know that the Draeger 5000 and Sotoxa devices have both had their issues:

The Dräger DrugTest 5000 (DDT5000) has shown varying accuracy levels, with some studies reporting false positives and false negatives. While it can be a valuable tool for initial screening, it's not perfect and should be confirmed by a lab test for definitive results.

False positives ranged from 65 percent of opiates flagged by SoToxa to 5 percent of marijuana positives. False negatives were also an issue. Thirty percent of cannabis samples deemed negative by SoToxa analyzers were found to be positive in blood tests.

[pdicamillo1]

Interesting article on the topic of Court-Ordered Mandatory Drug Testing:

https://nij.ojp.gov/topics/articles/detecting-fentanyl-use-through-court-ordered-mandatory-drug-testing

"Law enforcement and policymakers need timely, evidence-based intelligence of drug prevalence in criminal justice populations, including patterns of fentanyl and fentanyl-related compounds. This will help inform prevention and enforcement strategies, improve public health measures, and help increase compliance with probation and parole conditions."

[pdicamillo1]

Starting July 7, 2025, fentanyl will be added to the required drug testing panels used in the Federal Drug-Free Workplace Program, as announced by the Substance Abuse and Mental Health Services Administration (SAMHSA) and published by the Department of Health and Human Services (HHS) in the Federal Register. This means that federal agencies will be required to test for fentanyl in their drug testing programs, according to the updated guidelines.

Testing Panels: Fentanyl will be included in both urine and oral fluid tests

Here's a more detailed explanation:
Mandatory Guidelines:
The Federal Drug-Free Workplace Program is governed by the Mandatory Guidelines for Federal Workplace Drug Testing Programs, which are published by HHS in the Federal Register.
Revised Panels:
The recent revisions to the Mandatory Guidelines, published on January 16, 2025, include the addition of fentanyl to the authorized drug testing panels.
Effective Date:
The new guidelines, including the addition of fentanyl, become effective on July 7, 2025.
Public Health and Safety:
This change is intended to enhance public health and safety by addressing emerging issues and illicit drug use, particularly fentanyl, among federal employees.
Reasons for Addition:
Fentanyl is a powerful opioid that has become a major cause of overdose deaths in the United States. Adding it to the drug testing panel aims to deter its use and detect its presence in federal workplaces.
Other Changes:
The revisions also include other changes, such as removing methylenedioxyethylamphetamine (MDEA) from the panel and adding methylenedioxyamphetamine (MDA) as an initial test analyte

[pdicamillo1]

I think our best option is to ask the management team at Lifeloc during the annual shareholder meeting the purpose of the mixed-shelf offering. I can only offer my opinion and I just do not believe they are focused on anything other than the completion of the SpinDx device.

It is disappointing that we did not see any volume or interest from the LD microcap event or the recent conference where they showcased the SpinDx technology. We could really use a news driven event that brings in some volume to the stock.

[EdibleZone]

It says "which may be issued from time to time by the Company in connection with acquisitions by the Company of assets, businesses, or securities." This seems specifically for acquisitions.

[pdicamillo1]

I can only speculate but I do not believe the recent offering of securities will be used for the purchase or acquisition of another company. They want to be able to issue shares at will in the near future for SpinDx funding and developments. Big difference between issuing more shares at the current price of $3.00 vs. creating some buying interest first and then issuing them at let's say $6.00 or $10.00. It's almost an insult to current long-term shareholders if they were to issue more shares at current prices. They know how to move stock prices higher which would benefit everyone.

However, as of now we only have sellers at this $3.00 price level and no buyers. They need to create some buying interest and push it to the upside before diluting with more shares.

[EdibleZone]

Lifeloc is so small, who could they buy with just 825k?

[pdicamillo1]

I find it interesting that when Grok compares Lifeloc to Cannabix it states that BLOZF is riskier due to its pre-revenue status and higher valuation, the lack of revenue, overvaluation concerns, and competitive risks warrant caution.
Discussions note Cannabix’s higher market cap despite no revenue, suggesting it may be overvalued compared to LCTC, though both are speculative.

For Lifeloc it also states, A positive catalyst (e.g., a major contract or product launch) could drive significant upside, as seen in 2016–2017.

And you have to love this line: In 2016–2017, LCTC’s stock surged from $4–$7 to the mid-$20s following news of early-stage THC breathalyzer development. With SpinDx nearing commercialization, a similar catalyst could drive price. appreciation.

The mid $20's should be achievable with commercialization and would put the market cap on par with that of Cannabix which certainly does not seem unreasonable to assume.

[pdicamillo1]

When Grok was asked "What do you think of BLOZF Cannabix technologies as a stock investment?"

Cannabix Technologies, Inc. (BLOZF) is a Canadian-based company traded on the OTC market, focused on developing marijuana and alcohol breathalyzer technologies for law enforcement, workplaces, and laboratories. Below is an analysis of BLOZF as a potential stock investment, incorporating relevant information and critical considerations.
Positives
Innovative Product Pipeline:
Cannabix is developing tetrahydrocannabinol (THC) breathalyzers to detect recent marijuana use, addressing a growing need for accurate impairment testing in workplaces and roadside DUI enforcement. Their Breath Logix alcohol breathalyzer is already being deployed in settings like Montana and South Africa.

Strategic partnerships with Omega Laboratories and AlcoPro for marijuana breathalyzer commercialization and marketing enhance their market reach.

Recent advancements, such as validation with Omega Laboratories and presentations at industry conferences (e.g., Tennessee Safety and Health Conference), signal progress toward product adoption.

Market Opportunity:
The U.S. cannabis market is expanding amid legal reforms, increasing demand for reliable THC detection tools to address safety concerns.

The global breathalyzer market is growing due to stricter regulations on workplace safety and impaired driving, positioning Cannabix to capture a niche segment if their technology gains traction.

Stock Price Momentum:
BLOZF’s stock price has shown volatility, with a 52-week range of $0.15 to $0.643. As of April 2025, it was trading at approximately $0.43, reflecting a 140.82% increase over the past year.

Short-term technical indicators, such as buy signals from moving averages and a 3-month MACD, suggest positive momentum. The stock gained 18.75% on March 14, 2025, with increased trading volume.

Analyst Price Targets:
Analysts forecast a 30-day price target of $0.3807, a 38.04% increase from $0.2758, with long-term projections reaching $0.659 by 2050. These projections indicate speculative upside potential.

Risks and Concerns
Financial Performance:
Cannabix has no revenue and consistently reports losses. The latest quarterly net income was -435,370 CAD, with a price-to-earnings ratio of -13.28, reflecting ongoing unprofitability.

The company’s reliance on financing and lack of revenue make it a high-risk investment, as sustained losses could strain operations without successful product commercialization.

Valuation and Overvaluation Concerns:
Wall Street analysts consider BLOZF overvalued based on current fundamentals. Morningstar estimates the stock is trading at a 467% premium to its fair value.

The market cap of $43.75 million is significantly higher than Lifeloc Technologies (LCTC) at $7.33 million, despite Cannabix’s lack of revenue, suggesting speculative pricing.

Competitive Landscape:
Cannabix faces competition from companies like Lifeloc Technologies (LCTC), which already generates revenue, and larger players like Dräger. Its smaller size and pre-revenue status could limit its ability to compete.

The THC breathalyzer market is nascent, and unproven technology or delays in commercialization could erode investor confidence.

OTC Market Risks:
As an OTC stock, BLOZF is subject to high volatility, low liquidity, and wide bid-ask spreads, increasing trading risks. The stock’s small float (115.14 million shares) can lead to sharp price swings.

Lack of analyst coverage and institutional ownership reduces transparency and may signal limited professional investor confidence.

Regulatory and Market Uncertainty:
While cannabis legalization drives demand, evolving regulations could impact the adoption of THC breathalyzers. The technology’s acceptance by law enforcement and employers is not guaranteed.

The stock’s price is susceptible to hype, as noted in warnings about penny stocks and promotional activity.

Stock Performance
Price Range: 52-week low of $0.15 and high of $0.643. Current price around $0.43 (April 2025).

Market Cap: $43.75 million with 115,144,104 shares outstanding.

Volatility: The stock is 3.51% volatile with a beta of 1.64, indicating higher market risk.

Next Earnings: March 17, 2025, though no EPS estimates are available due to limited coverage.

Comparison to LCTC
Lifeloc (LCTC): Generates $2.06 million in quarterly revenue but has negative EPS (-$0.061 in Q3 2024). Its market cap is lower ($7.33 million), suggesting a less speculative valuation. LCTC’s SpinDx drug testing device is in beta, similar to Cannabix’s pre-commercial stage.

Cannabix (BLOZF): No revenue, higher market cap, and greater price volatility. Its focus on THC breathalyzers aligns with a unique market niche but carries higher risk due to unproven revenue streams.

Investor Sentiment: InvestorsHub discussions note Cannabix’s higher market cap despite no revenue, suggesting it may be overvalued compared to LCTC, though both are speculative.

Investment Considerations
Speculative Play: BLOZF is suitable for risk-tolerant investors betting on the successful commercialization of its THC breathalyzer. Positive developments, such as partnerships or product certifications, could drive significant upside, as seen in past spikes.

High Risk: The lack of revenue, negative earnings, and OTC status make it a high-risk investment. Investors should be prepared for volatility and potential losses.

Technical Outlook: Short-term bullish signals (e.g., moving averages, MACD) suggest potential for near-term gains, but long-term value depends on product execution.

Due Diligence: Monitor upcoming earnings (March 17, 2025) and news on partnerships or product validations. Use limit orders to manage wide bid-ask spreads.

Macroaxis Recommendation: A “Strong Sell” rating reflects concerns about fundamentals and risk, urging caution.

Recommendation
Cannabix Technologies (BLOZF) is a high-risk, high-reward speculative investment. Its innovative THC breathalyzer technology and recent partnerships offer growth potential, but the lack of revenue, overvaluation concerns, and competitive risks warrant caution. Compared to Lifeloc (LCTC), BLOZF is riskier due to its pre-revenue status and higher valuation, though it may appeal to investors focused on the cannabis testing niche. Limit exposure to a small portfolio allocation and consult a financial advisor to align with your risk tolerance.

[pdicamillo1]

When Grok (X's - Twitter's AI Platform) was asked "What do you think of LCTC Lifeloc Technologies as a stock investment?"

Lifeloc Technologies, Inc. (LCTC) is a small-cap company trading on the OTC market, specializing in breath alcohol and drug testing devices, primarily for law enforcement, workplace safety, and corrections. Below is an analysis of LCTC as a potential stock investment, based on available information and critical considerations:
Positives
Niche Market with Growth Potential:
Lifeloc operates in a specialized market for breathalyzers and drug testing devices, with applications in workplace safety, law enforcement, and emerging consumer markets. The global demand for such devices is growing due to increasing regulations around workplace safety and DUI enforcement.

Their development of innovative products like the SpinDx saliva drug testing device and collaborations (e.g., with Sandia Labs) could position them for future growth if commercialized successfully.

Recent Financial Developments:
Lifeloc secured $750,000 in financing from Diamond Bridge Capital, which could support product development or operational expansion.

The company reported a Q3 2024 revenue of $2.06 million, a 3% year-over-year increase, indicating modest growth.

Low Float and Potential for Volatility:
LCTC has a small public float of approximately 139,260 shares, which can lead to significant price swings with relatively low trading volume. This could benefit speculative investors if positive news (e.g., SpinDx commercialization) drives interest.

Historical Precedent:
In 2016–2017, LCTC’s stock surged from $4–$7 to the mid-$20s following news of early-stage THC breathalyzer development. With SpinDx nearing commercialization, a similar catalyst could drive price appreciation.

Risks and Concerns
Financial Performance:
Lifeloc’s recent earnings have been inconsistent. For Q3 2024, the company reported a GAAP EPS of -$0.061, missing expectations, and Q2 2024 showed a GAAP EPS of -$0.12. Negative earnings indicate operational challenges or high R&D costs.

The company does not pay dividends, limiting its appeal to income-focused investors.

Valuation and Liquidity:
LCTC is considered overvalued by some Wall Street analysts, with a high price-to-earnings ratio relative to its earnings.

The stock’s bid-ask spread is likely wide due to low liquidity (common for OTC stocks), making it harder to buy or sell at desired prices. A larger spread suggests fewer market participants, increasing trading risk.

Market and Competitive Risks:
The breathalyzer and drug testing market is competitive, with larger players like Dräger and Axon also active. Lifeloc’s smaller size and limited resources could hinder its ability to capture market share.

The SpinDx device, while promising, is still in beta testing, and there’s no guarantee of successful commercialization or market adoption.

Lack of Analyst Coverage:
LCTC has no analyst coverage, resulting in a lack of professional estimates for revenue or earnings growth. This makes it harder to assess its fair value or future prospects.

The absence of hedge fund ownership may indicate limited institutional confidence in the stock.

OTC Market Risks:
OTC stocks like LCTC are subject to higher volatility and lower regulatory oversight compared to major exchanges. Extended trading hours (pre- and post-market) may offer less liquidity and more volatile prices.

The stock’s low trading volume (average 3-month volume not specified but likely low given the float) increases the risk of price manipulation or difficulty exiting positions.

Stock Performance
Recent Price Range: Over the past 12 months, LCTC’s stock price ranged from $1.90 to $5.58. As of the latest data, it was trading at $2.75.

Market Cap: With 2,664,116 shares outstanding, the market cap is approximately $7.33 million at $2.75 per share.

Volatility: Insufficient data exists to quantify recent volatility, but the small float and OTC status suggest high price swings.

Investment Considerations
Speculative Opportunity: LCTC could be a speculative play for risk-tolerant investors betting on the successful commercialization of SpinDx or increased adoption of its breathalyzers. A positive catalyst (e.g., a major contract or product launch) could drive significant upside, as seen in 2016–2017.

High Risk: The company’s negative earnings, lack of analyst coverage, and competitive pressures make it a high-risk investment. Investors should be prepared for potential losses, especially given the OTC market’s inherent risks.

Due Diligence: The lack of comprehensive financial data and analyst insights means investors must conduct thorough research. Monitoring upcoming earnings (next report due March 14, 2025) and SpinDx beta testing updates will be critical.

Comparison to Peers: InvestorsHub discussions compare LCTC to Cannabix (BLOZF), a competitor with no revenue but a higher market cap. This suggests LCTC could be undervalued relative to peers, but it also highlights the speculative nature of the sector.

Recommendation
LCTC is a high-risk, high-reward investment suitable for speculative investors with a high tolerance for volatility and uncertainty. The potential for growth exists if SpinDx or other products gain traction, but negative earnings, low liquidity, and competitive pressures warrant caution. Limit orders are recommended to manage trading costs due to the likely wide bid-ask spread.

[pdicamillo1]

An effective shelf registration statement allows an issuer to be in a position to complete multiple offerings from time to time in the future without having the timing of any such offering delayed by a possible SEC review.

The shelf registration process allows an issuer to file a registration statement with the Securities and Exchange Commission (“SEC”) in order to register a public offering, when the issuer has no present intention to sell the securities being registered. A shelf registration statement permits multiple offerings off of the same shelf registration statement and it can be used for the sale of new securities by the issuer (“primary offerings”), the resale of outstanding securities held by securityholders (“secondary offerings”), or a combination of both.

With an effective shelf registration statement, when the issuer wants to offer securities, it takes them “off the shelf.” These “shelf takedowns” are usually offered pursuant to a base prospectus (contained in the registration statement) and a prospectus supplement. Securities are usually registered for sale either on a continuous or a delayed basis, although a portion of the securities may be offered immediately.

The primary advantages of a shelf registration statement are timing and certainty. An effective shelf registration statement enables an issuer to access the capital markets quickly when necessary or when market conditions are optimal. As noted above, once an issuer’s shelf registration statement has been declared effective, no SEC review is required in connection with subsequent takedowns.

[pdicamillo1]

Lifeloc on Friday filed to register up to 275,000 shares of their common stock through an acquisition shelf registration:

This prospectus relates to up to 275,000 shares of common stock, no par value (the “Common Stock”), of Lifeloc Technologies, Inc. (the “Company”), which may be issued from time to time by the Company in connection with acquisitions by the Company of assets, businesses, or securities. We expect that the terms of acquisitions involving the issuance of any such shares will be determined by direct negotiations with the owners or controlling persons of the assets, businesses or securities to be acquired, and that the shares of Common Stock issued will be valued at prices reasonably related to the market price of the Common Stock either at the time an agreement is entered into concerning the terms of the acquisition or at or about the time the shares are delivered.

This prospectus is part of an “acquisition shelf” registration statement on Form S-4 that we filed with the Securities and Exchange Commission, or the SEC, under the Securities Act of 1933, as amended, or the Securities Act, using an “acquisition shelf” registration process. This prospectus relates to an aggregate of up to 275,000 shares of common stock, no par value per share, of Lifeloc Technologies, Inc., a Colorado corporation (the “Company”), which may be issued from time to time by the Company in connection with acquisitions by the Company of assets, businesses, or securities.

[pdicamillo1]

I wasn't able to catch the first part of the presentation so I don't have the notes for that section but here's what I have from the last 15 minutes: 
Rapid drug testing market remains the best opportunity to grow by multiples.   
Legalization of marijuana only increases the need for rapid drug detection 
The recent US DOT rule requiring the availability of oral fluids as a drug testing option aligns with the first SpinDx offering. 
Spin DX offers a Simple effective drug test that can be done quickly and also be cost effective. 
Discriminating for delta 9 thc from other cannabinoids and metabolites.   This is the key differentiation from other available drug testing products.  There are currently no other products that do that.  
Current impairment has to include knowing the levels of delta 9 thc.  That’s the only thing that’s relevant.  
Currently analysis time is 13 minutes with a target of 8-10 minutes 
Utility patent and PCT patent applications have been filed. Second filing to follow.  
The Spin DX system has detected thc, cocaine, fentanyl, amphetamine, methamphetamine, morphine, MDMA, and benzodiazepines in both saliva and blood. 
Test identification options include drivers license bar code scan, Bluetooth manual entry and RFID badge.  
Firmware includes customizable drug cutoff values for local requirements.  
Greater recurring revenue from higher value consumable disks - $25/each.   Much greater revenue stream from the disk assays. Reader, collection kits and firmware subscription are all also good revenue streams.  
Talks with England and South Africa are about including different drugs of abuse and alines us with the flexibility of the technology.   Easily customized through different assay reagents.  
Beta testing towards end of 2nd quarter.  Still need to complete roadside testing kit. Disk is still in development.   Optimization and redesign work continues.  
First product release - the reader, oral fluid collection device and kit are still targeted for first quarter next year.  
Lifeloc wants to continually come to the market with new disks and functions.  Source of the liquid for test does not matter.  It is capable of analyzing blood - different product launch.  Breath collection is still a reasonable outcome for the device. 
Doubling revenue by 2028 simply on the saliva launch.  
All of the earnings are being used for SpinDx product launch.  
SpinDx device does not currently distinguish between delta 9 and delta 8 thc 
2 competitive devices do not test for current impairment.   Blood draw is costly and takes time for the officer to complete.  SpinDX Rapid test saves time and money and is more accurate.  

[Energy Manager]

I am registered for the livestream, as long as I can get away from work for a half an hour. I imagine the presentation will be mostly the information we already know about the device... as a matter of fact, we could probably make the presentation.

Anyway, hopefully it will gain the interest of some, that may be willing to invest in the stock on the open market. I anticipate one more round of funding may be needed to bring this to full-scale production, most likely on very similar terms of the recent debenture purchase agreement with Diamond Bridge Capital.

[pdicamillo1]

I am providing the link for the LD Microcap Invitational event here:

https://ldinv15.sequireevents.com/

Lifeloc Technologies will be presenting on Thursday April 10th track 3 at 3:00-3:30

I received an email from the organizer explaining that the event is full onsite but they have a livestream for attendees that can not make it. I am going to take it as a good sign that the event is at capacity.

No worries if you are unable to view it - I'll take notes and share with the board as long as I am able to attend it on the livestream.

Let's see if we can get some much needed volume to the upside this week!

[Energy Manager]

Sure is quiet...

[Energy Manager]

Thanks for going above and beyond....

[pdicamillo1]

Some quick news to share:
The CEO will be presenting at the Micro LD Invitational event next week and they will have a much larger team at IACT and will be showcasing the SpinDx device there.  

[Energy Manager]

Don't watch every tick, particularly with such a low float stock. If good news is announced, there are very little shares available, because insiders, Andy Lehman, and the few of us on this board own them all... I actually believe the opposite of what your thoughts are. I believe that no one is selling their shares, that there is little to no volume, and that most trades that are occurring, are just brokers balancing trades. It's apparent, by looking at the accumulation/distribution line on the one year chart of this stock, that the stock has been widely accumulated since June - up to the current date.

40% of the trades on Friday were sold short, or 200 shares of the 500. That does not mean that the short interest increased by 200, because those short trades were most likely closed the same day. The 2,000 shares you noticed on the ask, was most likely a market maker, trying to induce some selling, taking advantage of the overall market sell-off that occurred Friday - and it may have worked... your thoughts were that someone is putting downward pressure on the stock. They fire off a 100 - 200 shares at the bid, and drop the price down - trying to induce some more selling, then cover & accumulate.
Market Date FINRA
Non-Exempt Volume FINRA
Exempt Volume FINRA
Short Volume FINRA
Total Volume FINRA
Short Volume Ratio
2025-04-04 200 + 0 = 200 / 500 = 40.00
2025-04-03 100 + 0 = 100 / 201 = 49.75
2025-04-01 10 + 0 = 10 / 10 = 100.00
2025-03-21 1 + 0 = 1 / 21 = 4.76
2025-03-20 100 + 0 = 100 / 100 = 100.00
2025-03-19 10 + 0 = 10 / 10 = 100.00
2025-03-14 100 + 0 = 100 / 200 = 50.00
2025-03-11 500 + 0 = 500 / 7,644 = 6.54

Is Lifeloc undervalued? Yes, greatly in my opinion. Could we use a few good positive press releases? Of course... It will come...

[pdicamillo1]

I really find it hard to believe that LCTC is worth just $3.00/share. Cannabix is currently valued at 5.7 times that of Lifeloc. If the Lifeloc technology for the SpinDx proves itself worthy, it is infinitely better than the Cannabix device which can just test for marijuana with no quantitative aspect.

No one here has to pay me any mind but someone or something has held this stock down for a long time and continues to do so. In no logical universe should Lifeloc be worth one sixth the value of Cannabix. I would really love to find out what exactly is happening with the stock and why it seems like unlimited shares for sale. Every single time the stock has an uptick, shares come in for sale. With all the upcoming catalysts, who continues to offer up shares to sell?

The upcoming week is one of the most important events in the history of Lifeloc's existence. They have the opportunity to present a device that has been 10 years in the making. I can't wrap my head around how this is just a $3.00 stock.

[Energy Manager]

The basic fact that they said in their recent filing, that they intend to unveil the device at upcoming shows. Maybe timing wasn't right for some reason on the NDASA conference ???

[pdicamillo1]

Is there anything in this exclusive patent license agreement with Sandia that would be favorable or unfavorable to Lifeloc:

https://contracts.justia.com/companies/lifeloc-technologies-inc-3831/contract/1320919/

[pdicamillo1]

It's also the last day of the NDASA conference and trade show. What would make you think that they did not present the SpinDx at this show and will be waiting until IACT meeting to unveil it for the first time?

[pdicamillo1]

This event on Thursday also coincides with the LD microcap investor presentation date. I am going to email the CEO and try to find out which event he and the management team will be attending. I will keep you updated on any responses.

[pdicamillo1]

Looks like there's another 2,000 shares to go before we can clear out what is hopefully the last of the shares for sale. With the upcoming IACT conference and the LD microcap event next week seems like an odd time to want out of the stock. If for some reason the shares get bought up today, I will also make some stock purchases.

[Energy Manager]

Next week is the IACT Annual Meeting in Las Vegas, where Lifeloc is a sponsor, as well as an exhibitor - along with Draeger and Intoximeters. https://iactonline.org/page-1709724#conference-details

It's my opinion, that Lifeloc will display, and demonstrate their new SpinDx Oral Fluid Device at this conference for the first time publicly. Other big players in the field, such as Draeger, and Intoximeters will also be in attendance. It would be nice to have a PR hit the Dow Jones Newswire, Globe Newswire, Marketwire, PR Newswire, Reuters, etc... that coincides, and details the devices features and capabilities. Lifeloc needs brand awareness in the investment community - you can't gain interest in your company's common stock, if you remain silent.

The conference begins on Sunday, but the most relevant part of the entire meeting, will be a workshop held on Thursday.

Thursday - April 10th

Workshop 2: Oral Fluid Roadside Device Evaluation & Approval (Sponsored by the SOFT/AAFS Oral Fluid Committee)

Time: 8:00AM - 12:00PM

Chairs: Curt Harper, Ph.D. & Mandi Mohr

[Energy Manager]

Lifeloc does buy some of their fuel cells from other vendors - it could be Draeger. They manufacture most of what they use in their alcohol breathalyzers, but always good to have a back up source if they cannot obtain the required elements to manufacture their own.

[Energy Manager]

Lifeloc sells their fuel cells, as well as other items, to variety of other businesses in the same field, as well as electronic interlock devices. I'm not sure if they purchase anything from Draeger, or not... As far as the approved labs go, any DOT testing must have a split sample of the tested oral fluid, sent to an approved lab for a confirmatory test, to verify findings of the roadside test. Police will go by their states rules/laws. The accredited labs will come, I'm sure they are close to identifying several.

When at least two labs are accredited, and there will probably be many more than that, this will be a significant external milestone, in the advancement of bringing Lifeloc's device to market.

[EdibleZone]

I'm fairly certain they buy something from Drager, could it be the fuel cell?
Does the lack of DOT approved labs for saliva make it very difficult for Lifeloc to sell the SpinDx to police forces or trucking companies? How does it affect them? Thanks.

[Energy Manager]

Lifeloc sells its breathalyzers in over 60 different countries, so I'm sure there will be some impact by tariffs. They make their own platinum fuel cells in-house, right here in the good old USA.

I believe the sotaxa device has a dual collection, which meets DOT requirements, but the Draeger 5000 does not - it's just a swab in a cassette to the best of my knowledge.

[pdicamillo1]

Thanks. Do you have any idea if these tariffs have an effect on Lifeloc and its business operations? Are the fuel cells used for their alcohol breathalyzers produced domestically or overseas?
Do you know if the Draeger 5000 or the Sotaxa drug detection devices have the split sample tube device and are DOT approved?

[Energy Manager]

I know they have it in the device - I believe it was in the original, provisional patent. All oral fluid devices for THC detection are required to have it. There are also other parameters required as well - the medium in which the fluid is mixed in the tube, the tube must be transparent, and I believe there must be a lot#, or something to that affect, on each tube. I believe I posted about this about 6 months ago - and I'm going from my memory.

[pdicamillo1]

BLOZF Cannabix up near resistance at $0.47. Could see a nice move if it breaks through that level. I wonder if they are making progress at the NDASA show.

Does anyone remember SoberSafe (SOBR) - that thing currently has a market cap of less than half a million. What a disaster with that one. At one point SOBR was valued 5 times that of Lifeloc. That's nuts.